WHO’s mpox response aims to reduce disease burden, provides scope for developers
There is a huge opportunity for developers and manufacturers to advance novel prophylactic and treatment options, says GlobalData
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
KM Biologics
KM Biologics commences clinical trial of COVID-19 vaccine candidate
The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an…